Bronchoalveolar Lavage as a Research Tool

ABSTRACT

Researchers over the past 40 years have utilized bronchoalveolar lavage (BAL) as a tool to help expand our knowledge of pulmonary medicine. Many reports have documented BAL as a safe procedure for research subjects. New technologies, such as flow cytometry, have provided much needed insight into the mechanisms behind several pulmonary diseases. The concept of the lung as an easily accessible mucosal site to monitor local immune responses and treatment effects is evolving. Future BAL research with human subjects, aided by new technology, will undoubtedly yield clinically relevant information regarding biomarkers of disease and new therapeutic targets.

Bronchoalveolar lavage fluid - safety - cytometry - immunology - acellular

REFERENCES

• 1 Baughman R P. The uncertainties of bronchoalveolar lavage.  Eur Respir J. 1997;  10 1940-1942
• 2 Costabel U. Atlas of Bronchoalveolar Lavage. Philadelphia; Chapman & Hall Medical 1998: 91
• 3 Reynolds H Y. Use of bronchoalveolar lavage in humans: past necessity and future imperative.  Lung. 2000;  178 271-293
• 4 Rottoli P, Bargagli E. Is bronchoalveolar lavage obsolete in the diagnosis of interstitial lung disease?.  Curr Opin Pulm Med. 2003;  9 418-425
• 5 Veeraraghavan S, Latsi P I, Wells A U et al.. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia.  Eur Respir J. 2003;  22 239-244
• 6 Ouellette D R. The safety of bronchoscopy in a pulmonary fellowship program.  Chest. 2006;  130 1185-1190
• 7 Hart R, Classen M. Complications of diagnostic gastrointestinal endoscopy.  Endoscopy. 1990;  22 229-233
• 8 Pingleton S K, Harrison G F, Stechschulte D J et al.. Effect of location, pH, and temperature of instillate in bronchoalveolar lavage in normal volunteers.  Am Rev Respir Dis. 1983;  128 1035-1037
• 9 Strumpf I J, Feld M K, Cornelius M J, Keogh B A, Crystal R G. Safety of fiberoptic bronchoalveolar lavage in evaluation of interstitial lung disease.  Chest. 1981;  80 268-271
• 10 Djukanovic R, Wilson J W, Lai C K, Holgate S T, Howarth P H. The safety aspects of fiberoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma.  Am Rev Respir Dis. 1991;  143(4 Pt 1) 772-777
• 11 Hattotuwa K, Gamble E A, O'Shaughnessy T, Jeffery P K, Barnes N C. Safety of bronchoscopy, biopsy, and BAL in research patients with COPD.  Chest. 2002;  122 1909-1912
• 12 Stanley MWH-S, Michelle J, Iber C. Bronchoalveolar Lavage. New York; Igaku-Shoin 1991: 240
• 13 Huang Y C, Bassett M A, Levin D, Montilla T, Ghio A J. Acute phase reaction in healthy volunteers after bronchoscopy with lavage.  Chest. 2006;  129 1565-1569
• 14 Elston W J, Whittaker A J, Khan L N et al.. Safety of research bronchoscopy, biopsy and bronchoalveolar lavage in asthma.  Eur Respir J. 2004;  24 375-377
• 15 Van Vyve T, Chanez P, Bousquet J et al.. Safety of bronchoalveolar lavage and bronchial biopsies in patients with asthma of variable severity.  Am Rev Respir Dis. 1992;  146 116-121
• 16 Busse W W, Wanner A, Adams K et al.. Investigative bronchoprovocation and bronchoscopy in airway diseases.  Am J Respir Crit Care Med. 2005;  172 807-816
• 17 Haslam P L, Baughman R P. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL.  Eur Respir J. 1999;  14 245-248
• 18 Rennard S I, Ghafouri M, Thompson A B et al.. Fractional processing of sequential bronchoalveolar lavage to separate bronchial and alveolar samples.  Am Rev Respir Dis. 1990;  141 208-217
• 19 Lam S, Leriche J C, Kijek K, Phillips D. Effect of bronchial lavage volume on cellular and protein recovery.  Chest. 1985;  88 856-859
• 20 Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee.  Am Rev Respir Dis. 1990;  141(5 Pt 2) S169-S202
• 21 Jones K P, Edwards J H, Reynolds S P, Peters T J, Davies B H. A comparison of albumin and urea as reference markers in bronchoalveolar lavage fluid from patients with interstitial lung disease.  Eur Respir J. 1990;  3 152-156
• 22 Dargaville P A, South M, Vervaart P, McDougall P N. Validity of markers of dilution in small volume lung lavage.  Am J Respir Crit Care Med. 1999;  160 778-784
• 23 Rennard S I, Basset G, Lecossier D et al.. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution.  J Appl Physiol. 1986;  60 532-538
• 24 Marcy T W, Merrill W W, Rankin J A, Reynolds H Y. Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage.  Am Rev Respir Dis. 1987;  135 1276-1280
• 25 Ward C, Duddridge M, Fenwick J et al.. The origin of water and urea sampled at bronchoalveolar lavage in asthmatic and control subjects.  Am Rev Respir Dis. 1992;  146 444-447
• 26 Ishizaka A, Watanabe M, Yamashita T et al.. New bronchoscopic microsample probe to measure the biochemical constituents in epithelial lining fluid of patients with acute respiratory distress syndrome.  Crit Care Med. 2001;  29 896-898
• 27 Pugin J, Verghese G, Widmer M C, Matthay M A. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome.  Crit Care Med. 1999;  27 304-312
• 28 Yamazaki K, Ogura S, Ishizaka A, Oh-hara T, Nishimura M. Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid.  Am J Respir Crit Care Med. 2003;  168 1304-1307
• 29 Sasabayashi M, Yamazaki Y, Tsushima K, Hatayama O, Okabe T. Usefulness of bronchoscopic microsampling to detect the pathogenic bacteria of respiratory infection.  Chest. 2007;  131 474-479
• 30 Larsson K, Tornling G, Gavhed D, Muller-Suur C, Palmberg L. Inhalation of cold air increases the number of inflammatory cells in the lungs in healthy subjects.  Eur Respir J. 1998;  12 825-830
• 31 Reynolds H Y. Lung inflammation and fibrosis: an alveolar macrophage-centered perspective from the 1970s to 1980s.  Am J Respir Crit Care Med. 2005;  171 98-102
• 32 Carre P C, Mortenson R L, King Jr T E et al.. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis: a potential mechanism for the recruitment and activation of neutrophils in lung fibrosis.  J Clin Invest. 1991;  88 1802-1810
• 33 Hunninghake G W, Gadek J E, Fales H M, Crystal R G. Human alveolar macrophage-derived chemotactic factor for neutrophils: stimuli and partial characterization.  J Clin Invest. 1980;  66 473-483
• 34 Merrill W W, Naegel G P, Matthay R A, Reynolds H Y. Alveolar macrophage-derived chemotactic factor: kinetics of in vitro production and partial characterization.  J Clin Invest. 1980;  65 268-276
• 35 Holt P G, Oliver J, Bilyk N et al.. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages.  J Exp Med. 1993;  177 397-407
• 36 Peters-Golden M. The alveolar macrophage: the forgotten cell in asthma.  Am J Respir Cell Mol Biol. 2004;  31 3-7
• 37 Lehnert B E, Valdez Y E, Sebring R J et al.. Airway intra-luminal macrophages: evidence of origin and comparisons to alveolar macrophages.  Am J Respir Cell Mol Biol. 1990;  3 377-391
• 38 Lofdahl J M, Wahlstrom J, Skold C M. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers.  Clin Exp Immunol. 2006;  145 428-437
• 39 Wu H M, Jin M, Marsh C B. Toward functional proteomics of alveolar macrophages.  Am J Physiol Lung Cell Mol Physiol. 2005;  288 L585-L595
• 40 Frank J A, Wray C M, McAuley D F, Schwendener R, Matthay M A. Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury.  Am J Physiol Lung Cell Mol Physiol. 2006;  291 L1191-L1198
• 41 Fehrenbach H, Zissel G, Goldmann T et al.. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis.  Eur Respir J. 2003;  21 421-428
• 42 Baughman R P, Drent M, Kavuru M et al.. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.  Am J Respir Crit Care Med. 2006;  174 795-802
• 43 Berenson C S, Garlipp M A, Grove L J, Maloney J, Sethi S. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease.  J Infect Dis. 2006;  194 1375-1384
• 44 Hodge S, Hodge G, Scicchitano R, Reynolds P N, Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells.  Immunol Cell Biol. 2003;  81 289-296
• 45 Berenson C S, Wrona C T, Grove L J et al.. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease.  Am J Respir Crit Care Med. 2006;  174 31-40
• 46 De Brauwer E I, Jacobs J A, Nieman F et al.. Cytocentrifugation conditions affecting the differential cell count in bronchoalveolar lavage fluid.  Anal Quant Cytol Histol. 2000;  22 416-422
• 47 Mordelet-Dambrine M, Arnoux A, Stanislas-Leguern G et al.. Processing of lung lavage fluid causes variability in bronchoalveolar cell count.  Am Rev Respir Dis. 1984;  130 305-306
• 48 Saltini C, Hance A J, Ferrans V J et al.. Accurate quantification of cells recovered by bronchoalveolar lavage.  Am Rev Respir Dis. 1984;  130 650-658
• 49 Curtis J L. Cell-mediated adaptive immune defense of the lungs.  Proc Am Thorac Soc. 2005;  2 412-416
• 50 Lehmann C, Wilkening A, Leiber D et al.. Lymphocytes in the bronchoalveolar space reenter the lung tissue by means of the alveolar epithelium, migrate to regional lymph nodes, and subsequently rejoin the systemic immune system.  Anat Rec. 2001;  264 229-236
• 51 Tsao T C, Chen C H, Hong J H et al.. Shifts of T4/T8 T lymphocytes from BAL fluid and peripheral blood by clinical grade in patients with pulmonary tuberculosis.  Chest. 2002;  122 1285-1291
• 52 Hodge G, Hodge S, Reynolds P N, Holmes M. Compartmentalization of intracellular proinflammatory cytokines in bronchial intraepithelial T cells of stable lung transplant patients.  Clin Exp Immunol. 2006;  145 413-419
• 53 Twigg H L, Soliman D M, Day R B et al.. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection.  Am J Respir Crit Care Med. 1999;  159(5 Pt 1) 1439-1444
• 54 Twigg III H L, Spain B A, Soliman D M et al.. Production of interferon-gamma by lung lymphocytes in HIV-infected individuals.  Am J Physiol. 1999;  276(2 Pt 1) L256-L262
• 55 Brenchley J M, Schacker T W, Ruff L E et al.. CD4 + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.  J Exp Med. 2004;  200 749-759
• 56 Mehandru S, Poles M A, Tenner-Racz K et al.. Primary HIV-1 infection is associated with preferential depletion of CD4 + T lymphocytes from effector sites in the gastrointestinal tract.  J Exp Med. 2004;  200 761-770
• 57 Ely K H, Cookenham T, Roberts A D, Woodland D L. Memory T cell populations in the lung airways are maintained by continual recruitment.  J Immunol. 2006;  176 537-543
• 58 Delude R L. Flow cytometry.  Crit Care Med. 2005;  33(Suppl 12) S426-S428
• 59 Kaleem Z. Flow cytometric analysis of lymphomas: current status and usefulness.  Arch Pathol Lab Med. 2006;  130 1850-1858
• 60 Betts M R, Brenchley J M, Price D A et al.. Sensitive and viable identification of antigen-specific CD8 + T cells by a flow cytometric assay for degranulation.  J Immunol Methods. 2003;  281 65-78
• 61 Morgan E, Varro R, Sepulveda H et al.. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology.  Clin Immunol. 2004;  110 252-266
• 62 Kern F, LiPira G, Gratama J W, Manca F, Roederer M. Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer.  Trends Immunol. 2005;  26 477-484
• 63 Barry S M, Condez A, Johnson M A, Janossy G. Determination of bronchoalveolar lavage leukocyte populations by flow cytometry in patients investigated for respiratory disease.  Cytometry. 2002;  50 291-297
• 64 Roberts S D, Kohli L L, Wood K L, Wilkes D S, Knox K S. CD4 + CD28-T cells are expanded in sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2005;  22 13-19
• 65 Skold C M, Eklund A, Hallden G, Hed J. Autofluorescence in human alveolar macrophages from smokers: relation to cell surface markers and phagocytosis.  Exp Lung Res. 1989;  15 823-835
• 66 Smith P A, Kohli L M, Wood K L et al.. Cytometric analysis of BAL T cells labeled with a standardized antibody cocktail correlates with immunohistochemical staining.  Cytometry. 2006;  70 170-178
• 67 Moyron-Quiroz J E, Rangel-Moreno J, Kusser K et al.. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity.  Nat Med. 2004;  10 927-934
• 68 Ersch J, Tschernig T, Stallmach T. Frequency and potential cause of bronchus-associated lymphoid tissue in fetal lungs.  Pediatr Allergy Immunol. 2005;  16 295-298
• 69 Rangel-Moreno J, Hartson L, Navarro C et al.. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis.  J Clin Invest. 2006;  116 3183-3194
• 70 Suda T, Chida K, Hayakawa H et al.. Development of bronchus-associated lymphoid tissue in chronic hypersensitivity pneumonitis.  Chest. 1999;  115 357-363
• 71 Tschernig T, Pabst R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases.  Pathobiology. 2000;  68 1-8
• 72 Hiller A S, Tschernig T, Kleemann W J, Pabst R. Bronchus-associated lymphoid tissue (BALT) and larynx-associated lymphoid tissue (LALT) are found at different frequencies in children, adolescents and adults.  Scand J Immunol. 1998;  47 159-162
• 73 Sue-Chu M, Karjalainen E M, Altraja A et al.. Lymphoid aggregates in endobronchial biopsies from young elite cross-country skiers.  Am J Respir Crit Care Med. 1998;  158 597-601
• 74 Bienenstock J, McDermott M R. Bronchus- and nasal-associated lymphoid tissues.  Immunol Rev. 2005;  206 22-31
• 75 Prussin C, Metcalfe D D. 5. IgE, mast cells, basophils, and eosinophils.  J Allergy Clin Immunol. 2006;  117(Suppl 2) S450-S456
• 76 Kariyawasam H H, Robinson D S. The eosinophil: the cell and its weapons, the cytokines, its locations.  Semin Respir Crit Care Med. 2006;  27 117-127
• 77 Liu L Y, Sedgwick J B, Bates M E et al.. Decreased expression of membrane IL-5 receptor alpha on human eosinophils, I: Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge.  J Immunol. 2002;  169 6452-6458
• 78 Liu L Y, Jarjour N N, Busse W W, Kelly E A. Chemokine receptor expression on human eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental antigen challenge.  J Allergy Clin Immunol. 2003;  112 556-562
• 79 Das A M, Vaddi K G, Solomon K A et al.. Selective inhibition of eosinophil influx into the lung by small molecule CC chemokine receptor 3 antagonists in mouse models of allergic inflammation.  J Pharmacol Exp Ther. 2006;  318 411-417
• 80 Julius P, Hochheim D, Boser K et al.. Interleukin-5 receptors on human lung eosinophils after segmental allergen challenge.  Clin Exp Allergy. 2004;  34 1064-1070
• 81 Hogaboam C M, Carpenter K J, Schuh J M et al.. The therapeutic potential in targeting CCR5 and CXCR4 receptors in infectious and allergic pulmonary disease.  Pharmacol Ther. 2005;  107 314-328
• 82 Luijk B, Lindemans C A, Kanters D et al.. Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge.  J Allergy Clin Immunol. 2005;  115 997-1003
• 83 Woodman L, Sutcliffe A, Kaur D et al.. Chemokine concentrations and mast cell chemotactic activity in BAL fluid in patients with eosinophilic bronchitis and asthma, and in normal control subjects.  Chest. 2006;  130 371-378
• 84 Akbari O, Faul J L, Hoyte E G et al.. CD4 + invariant T-cell-receptor + natural killer T cells in bronchial asthma.  N Engl J Med. 2006;  354 1117-1129
• 85 Jain P, Sandur S, Meli Y et al.. Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates.  Chest. 2004;  125 712-722
• 86 Hage C A, Davis T E, Egan L et al.. Diagnosis of pulmonary histoplasmosis and blastomycosis by detection of antigen in bronchoalveolar lavage fluid using an improved second-generation enzyme-linked immunoassay.  Respir Med. 2007;  101 43-47
• 87 Wheat L J, Garringer T, Brizendine E, Connolly P. Diagnosis of histoplasmosis by antigen detection based upon experience at the histoplasmosis reference laboratory.  Diagn Microbiol Infect Dis. 2002;  43 29-37
• 88 Musher B, Fredricks D, Leisenring W et al.. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid.  J Clin Microbiol. 2004;  42 5517-5522
• 89 Kralovic S M, Rhodes J C. Utility of routine testing of bronchoalveolar lavage fluid for cryptococcal antigen.  J Clin Microbiol. 1998;  36 3088-3089
• 90 Baughman R P, Rhodes J C, Dohn M N, Henderson H, Frame P T. Detection of cryptococcal antigen in bronchoalveolar lavage fluid: a prospective study of diagnostic utility.  Am Rev Respir Dis. 1992;  145 1226-1229
• 91 Malabonga V M, Basti J, Kamholz S L. Utility of bronchoscopic sampling techniques for cryptococcal disease in AIDS.  Chest. 1991;  99 370-372
• 92 Hage C A, Reynolds J M, Durkin M, Wheat L J, Knox K S. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid.  J Clin Microbiol. 2007;  45 676-677
• 93 Hayden R T, Uhl J R, Qian X et al.. Direct detection of Legionella species from bronchoalveolar lavage and open lung biopsy specimens: comparison of LightCycler PCR, in situ hybridization, direct fluorescence antigen detection, and culture.  J Clin Microbiol. 2001;  39 2618-2626
• 94 Wattiez R, Falmagne P. Proteomics of bronchoalveolar lavage fluid.  J Chromatogr B Analyt Technol Biomed Life Sci. 2005;  815 169-178
• 95 Magi B, Bargagli E, Bini L, Rottoli P. Proteome analysis of bronchoalveolar lavage in lung diseases.  Proteomics. 2006;  6 6354-6369
• 96 Hirsch J, Hansen K C, Burlingame A L, Matthay M A. Proteomics: current techniques and potential applications to lung disease.  Am J Physiol Lung Cell Mol Physiol. 2004;  287 L1-L23
• 97 Bowler R P, Ellison M C, Reisdorph N. Proteomics in pulmonary medicine.  Chest. 2006;  130 567-574
• 98 Chiu L M, Amsden G W. Intrapulmonary pharmacokinetics of antibacterial agents: implications for therapeutics.  Am J Respir Med. 2002;  1 201-209
• 99 Capitano B, Mattoes H M, Shore E et al.. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.  Chest. 2004;  125 965-973
• 100 Conte Jr J E, Golden J A, McIver M, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.  Int J Antimicrob Agents. 2006;  28 114-121
• 101 Conte Jr J E, Golden J A, Kelley M G, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.  Int J Antimicrob Agents. 2005;  26 449-456
• 102 Conte Jr J E, Golden J A, Kelly M G, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.  Int J Antimicrob Agents. 2005;  25 523-529
• 103 Creuwels L A, van Golde L M, Haagsman H P. The pulmonary surfactant system: biochemical and clinical aspects.  Lung. 1997;  175 1-39
• 104 Rooney S A. The surfactant system and lung phospholipid biochemistry.  Am Rev Respir Dis. 1985;  131 439-460
• 105 Wright J R, Youmans D C. Pulmonary surfactant protein A stimulates chemotaxis of alveolar macrophage.  Am J Physiol. 1993;  264(4 Pt 1) L338-L344
• 106 Juers J A, Rogers R M, McCurdy J B, Cook W W. Enhancement of bactericidal capacity of alveolar macrophages by human alveolar lining material.  J Clin Invest. 1976;  58 271-275
• 107 van Iwaarden F, Welmers B, Verhoef J, Haagsman H P, van Golde L M. Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages.  Am J Respir Cell Mol Biol. 1990;  2 91-98
• 108 Weissbach S, Neuendank A, Pettersson M, Schaberg T, Pison U. Surfactant protein A modulates release of reactive oxygen species from alveolar macrophages.  Am J Physiol. 1994;  267(6 Pt 1) L660-L666
• 109 Ansfield M J, Benson B J. Identification of the immunosuppressive components of canine pulmonary surface active material.  J Immunol. 1980;  125 1093-1098
• 110 Wilsher M L, Hughes D A, Haslam P L. Immunoregulatory properties of pulmonary surfactant: influence of variations in the phospholipid profile.  Clin Exp Immunol. 1988;  73 117-122
• 111 Wilsher M L, Hughes D A, Haslam P L. Immunoregulatory properties of pulmonary surfactant: effect of lung lining fluid on proliferation of human blood lymphocytes.  Thorax. 1988;  43 354-359
• 112 Possmayer F. A proposed nomenclature for pulmonary surfactant-associated proteins.  Am Rev Respir Dis. 1988;  138 990-998
• 113 Gunther A, Siebert C, Schmidt R et al.. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema.  Am J Respir Crit Care Med. 1996;  153 176-184
• 114 Hite R D, Seeds M C, Bowton D L et al.. Surfactant phospholipid changes after antigen challenge: a role for phosphatidylglycerol in dysfunction.  Am J Physiol Lung Cell Mol Physiol. 2005;  288 L610-L617
• 115 Erpenbeck V J, Schmidt R, Gunther A, Krug N, Hohlfeld J M. Surfactant protein levels in bronchoalveolar lavage after segmental allergen challenge in patients with asthma.  Allergy. 2006;  61 598-604
• 116 Gunther A, Schmidt R, Nix F et al.. Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis.  Eur Respir J. 1999;  14 565-573
• 117 Griese M, Essl R, Schmidt R et al.. Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients.  Respir Res. 2005;  6 133
• 118 Daimon T, Tajima S, Oshikawa K et al.. KL-6 and surfactant proteins A and D in serum and bronchoalveolar lavage fluid in patients with acute eosinophilic pneumonia.  Intern Med. 2005;  44 811-817
• 119 Kunitake R, Kuwano K, Yoshida K et al.. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis.  Respiration. 2001;  68 488-495
• 120 Xing J C, Chen W H, Han W H et al.. Changes of tumor necrosis factor, surfactant protein A, and phospholipids in bronchoalveolar lavage fluid in the development and progression of coal workers' pneumoconiosis.  Biomed Environ Sci. 2006;  19 124-129
• 121 Kuroki Y, Takahashi H, Chiba H, Akino T. Surfactant proteins A and D: disease markers.  Biochim Biophys Acta. 1998;  1408 334-345
• 122 Takahashi H, Sano H, Chiba H, Kuroki Y. Pulmonary surfactant proteins A and D: innate immune functions and biomarkers for lung diseases.  Curr Pharm Des. 2006;  12 589-598
• 123 Twigg III H L. Humoral immune defense (antibodies): recent advances.  Proc Am Thorac Soc. 2005;  2 417-421
• 124 Merrill W W, Naegel G P, Olchowski J J, Reynolds H Y. Immunoglobulin G subclass proteins in serum and lavage fluid of normal subjects: quantitation and comparison with immunoglobulins A and E.  Am Rev Respir Dis. 1985;  131 584-587
• 125 Reynolds H Y, Merrill W M, Amento E P, Naegel G P. Immunoglobulin A in secretions from the lower human respiratory tract.  Adv Exp Med Biol. 1978;  107 553-564
• 126 Holter J F, Weiland J E, Pacht E R, Gadek J E, Davis W B. Protein permeability in the adult respiratory distress syndrome: loss of size selectivity of the alveolar epithelium.  J Clin Invest. 1986;  78 1513-1522
• 127 Hol B E, van de Graaf E A, Out T A, Hische E A, Jansen H M. IgM in the airways of asthma patients.  Int Arch Allergy Appl Immunol. 1991;  96 12-18
• 128 Reynolds S P, Edwards J H, Jones K P, Davies B H. Immunoglobulin and antibody levels in bronchoalveolar lavage fluid from symptomatic and asymptomatic pigeon breeders.  Clin Exp Immunol. 1991;  86 278-285
• 129 Wilson D R, Merrett T G, Varga E M et al.. Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics.  Am J Respir Crit Care Med. 2002;  165 22-26
• 130 Bergmann M, Jonasson S, Klause N et al.. Analysis of immunoglobulins in sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1997;  14 139-145
• 131 Out T A, van de Graaf E A, van den Berg N J, Jansen H M. IgG subclasses in bronchoalveolar lavage fluid from patients with asthma.  Scand J Immunol. 1991;  33 719-727
• 132 Qvarfordt I, Riise G C, Andersson B A, Larsson S. IgG subclasses in smokers with chronic bronchitis and recurrent exacerbations.  Thorax. 2001;  56 445-449
• 133 Qvarfordt I, Riise G C, Larsson S et al.. Immunological findings in blood and bronchoalveolar lavage fluid in chronic bronchitis patients with recurrent infectious exacerbations.  Eur Respir J. 1998;  11 46-54
• 134 Fahy R J, Diaz P T, Hart J, Wewers M D. BAL and serum IgG levels in healthy asymptomatic HIV-infected patients.  Chest. 2001;  119 196-203
• 135 Gordon S B, Miller D E, Day R B et al.. Pulmonary immunoglobulin responses to Streptococcus pneumoniae are altered but not reduced in human immunodeficiency virus-infected Malawian adults.  J Infect Dis. 2003;  188 666-670
• 136 Armbruster C, Krugluger W, Huber M, Stephan K. Immunoglobulin G Fc(gamma) receptor expression on polymorphonuclear cells in bronchoalveolar lavage fluid of HIV-infected and HIV-seronegative patients with bacterial pneumonia.  Clin Chem Lab Med. 2004;  42 192-197